Genvor Inc. Files Q1 2025 10-Q

TL;DR

Genvor Inc. 10-Q filed. Q1 2025 results out.

AI Summary

Genvor Inc. filed its 10-Q for the period ending December 31, 2024. The company, previously known as Allure Worldwide, Inc., is incorporated in Nevada and operates in the agriculture production sector. Its fiscal year ends on September 30th. The filing includes financial data for the first quarter of fiscal year 2025, covering the period from October 1, 2024, to December 31, 2024.

Why It Matters

This filing provides investors with an update on Genvor Inc.'s financial performance and position for the first quarter of its 2025 fiscal year, offering insights into its operational status.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing standard financial information.

Key Numbers

• Q1 2025 — Fiscal Quarter (Reporting period for the 10-Q)
• 2024-12-31 — Period End Date (End date of the reporting period)
• 2025-08-15 — Filing Date (Date the 10-Q was submitted to the SEC)

Key Players & Entities

• Genvor Inc. (company) — Filer of the 10-Q
• Allure Worldwide, Inc. (company) — Former name of Genvor Inc.
• 2024-12-31 (date) — Period of report for the 10-Q
• 2025-08-15 (date) — Filing date of the 10-Q
• 0930 (date) — Fiscal year end

FAQ

Key Financial Figures

• $0.001 — ction 12(g) of the Act: Common Stock, $0.001 par value (Title of class) Indicate

Filing Documents

• gnvr_10q.htm (10-Q) — 601KB
• ex31_1.htm (EX-31.1) — 13KB
• ex31_2.htm (EX-31.2) — 12KB
• ex32_1.htm (EX-32.1) — 4KB
• ex32_2.htm (EX-32.2) — 4KB
• image_001.gif (GRAPHIC) — 4KB
• 0001903596-25-000416.txt ( ) — 3479KB
• gnvr-20241231.xsd (EX-101.SCH) — 26KB
• gnvr-20241231_cal.xml (EX-101.CAL) — 33KB
• gnvr-20241231_def.xml (EX-101.DEF) — 143KB
• gnvr-20241231_lab.xml (EX-101.LAB) — 257KB
• gnvr-20241231_pre.xml (EX-101.PRE) — 229KB
• gnvr_10q_htm.xml (XML) — 400KB

Legal Proceedings

Item 1. Legal Proceedings 22

Risk Factors

Item 1A. Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 22 Exhibit Index 22

Signatures

Signatures 23 PART 1 - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements GENVOR INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS December 31, September 30, 2024 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 581 $ 373 Prepaid expense 12,024 21,305 Total Current Assets 12,605 21,678 NON-CURRENT ASSETS: Property and equipment, net 13,444 13,902 Total Non-current Assets 13,444 13,902 Total Assets $ 26,049 $ 35,580 LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Convertible note payable, net $ 10,741 $ 7,408 Notes payable 897,000 897,000 Interest payable 625 121 Accrued professional fees 262,543 253,264 Accrued research and development fees 258,080 194,656 Accrued payroll liability and compensation 301,425 282,846 Accrued liabilities and other payables - related parties 87,266 65,665 SBA loan 48,750 48,750 Total Current Liabilities 1,866,430 1,749,710 Total Liabilities 1,866,430 1,749,710 Commitments and Contingencies (Note 6) — STOCKHOLDERS' DEFICIT: Preferred stock, $ 0.001 par value; 20,000,000 shares authorized; Series A Preferred Stock, 10 shares authorized; 6 shares issued and outstanding at December 31, 2024 and September 30, 2024 — — Series B Preferred Stock, 2,500,000 shares authorized; 2,060,536 shares issued and 1,558,024 shares outstanding at December 31, 2024 and September 30, 2024 2,061 2,061 Common stock, $ 0.001 par value; 300,000,000 shares authorized; 24,904,608 and 20,029,608 shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively 24,905 20,030 Additional paid-in capital 24,038,169 19,168,044 Less: series B preferred stock held in treasury, at cost; 502,512 shares at December 31, 2024 and September 30, 2024 ( 300,000 ) ( 300,000 ) Accumulated deficit ( 25,605,516 ) ( 20,604,265 ) Total Stockholders' Deficit ( 1,840,381 ) ( 1,714,130 ) Total Liabilities and Stockholders' Deficit $ 26,049 $ 35,580 See accompanying

Business

Business Plan and Strategy Genvor's business strategy centers on leveraging its proprietary BioCypher Algorithm, an AI-driven peptide discovery platform, to create sustainable agricultural solutions that optimize crop performance across diverse growing conditions. The Company's peptide technologies are designed to enhance yields, improve stress tolerance, and deliver nutrient optimization while addressing critical agricultural challenges including plant diseases, toxins, bacteria, and fungi. These innovations are designed to support farmers and growers worldwide by improving agricultural productivity, reducing chemical inputs, and enhancing economic outcomes through residue-free solutions that meet evolving regulatory requirements and consumer demands. The Company is advancing its portfolio of engineered peptide technologies through its proprietary BioCypher Algorithm, which accelerates the discovery and validation of commercial-grade peptide solutions. Genvor's platform supports multiple formulation approaches including foliar applications, transgenic seed traits, and seed treatment delivery systems, creating cross-crop scalability opportunities in row crops and specialty crops. The Company is leveraging its extensive peptide library of 50,000+ designed peptides to address high-value agricultural performance applications including yield enhancement, stress tolerance, nutrient use efficiency, and biological crop protection, as well as adjacent opportunities in animal health and feed optimization. Notable validation includes the Company's transgenic corn peptide AGM182, which demonstrated 72% reduction in fungal growth and 98% reduction in aflatoxin in USDA trials. Genvor's commercial model employs a licensing-first strategy centered on forming strategic partnerships, joint development agreements (JDAs), and licensing arrangements that create mutual competitive advantages. The Company's approach enables agricultural leaders to access validated peptide technolog

View Full Filing

View this 10-Q filing on SEC EDGAR